Med2Date β€” Clinical Guidelines
Home Cardiology Cardiac Tamponade

Cardiac Tamponade

Last updated 15 May 2026 Β· Pericardial disease
🎧 Cardiac Tamponade β€” deep-dive podcast

πŸ“‹ Key Information Summary

πŸ“‹
  • Cardiac tamponade is a life-threatening condition caused by accumulation of fluid in the pericardial space, compressing the heart and impairing diastolic filling.
  • Beck's triad β€” hypotension, muffled heart sounds, and jugular venous distension β€” is the classic clinical triad but is present in only a minority of patients at initial presentation.
  • Pulsus paradoxus (an inspiratory fall in systolic BP >10 mmHg) is a sensitive clinical sign; measure with a sphygmomanometer by noting the first and last Korotkoff sounds heard during slow deflation.
  • Transthoracic echocardiography (TTE) is the primary diagnostic modality: look for right atrial (RA) collapse in late diastole, right ventricular (RV) collapse in early diastole, and inferior vena cava (IVC) plethora (>50% inspiratory collapse absent).
  • Hemodynamic hallmark is equalization of intracardiac pressures (RA, RV diastolic, pulmonary capillary wedge, and intrapericardial pressures all within 5 mmHg of each other) β€” confirmed on right heart catheterisation.
  • Compensatory tachycardia and systemic vasoconstriction maintain cardiac output early; decompensation leads to obstructive shock and cardiac arrest (PEA rhythm).
  • Immediate resuscitation: IV fluid bolus (500–1000 mL crystalloid), avoid positive-pressure ventilation (including non-invasive ventilation with high pressures), position patient sitting upright if tolerated.
  • Definitive treatment is urgent drainage β€” emergency pericardiocentesis (subxiphoid approach, echo-guided preferred) or surgical pericardial window if loculated, recurrent, or haemorrhagic effusion.
  • Complications of pericardiocentesis include cardiac chamber puncture, pneumothorax, coronary artery laceration, and arrhythmia β€” echo guidance reduces major complication rate from ~5% to <1%.
  • All pericardial fluid must be sent for biochemistry (protein, LDH, glucose, ADA), cytology, microbiology (Gram stain, culture, TB culture/PCR), and cell count.
  • Common aetiologies in Australia: malignancy (lung, breast, lymphoma), idiopathic/viral pericarditis, uraemia, hypothyroidism, post-cardiac surgery, and tuberculosis (especially in immunocompromised and ATSI communities).
  • Monitor for reaccumulation with serial echocardiography; treat the underlying cause β€” antineoplastic therapy, dialysis, thyroid replacement, or anti-tuberculous therapy as appropriate.
🎬 Cardiac Tamponade β€” clinical explainer

Introduction & Australian Epidemiology

Cardiac tamponade is a medical emergency in which fluid accumulation within the pericardial sac raises intrapericardial pressure sufficiently to compress cardiac chambers, impair diastolic filling, and reduce cardiac output. If untreated, progressive obstructive shock leads to pulseless electrical activity (PEA) arrest and death.

The pericardium normally contains 15–50 mL of serous fluid. Tamponade physiology can develop acutely with as little as 100–200 mL of fluid if accumulation is rapid (e.g., traumatic haemopericardium), or may require >1–2 L if fluid accumulates slowly, allowing the pericardium to stretch and accommodate.

Australian Epidemiology

  • Pericardial effusion is detected on echocardiography in approximately 3–5% of patients admitted to Australian tertiary hospitals with cardiac complaints.
  • Malignancy is the most common cause of large pericardial effusions and tamponade in adults in Australia, with lung cancer, breast cancer, and lymphoma predominating.
  • Post-cardiac surgery tamponade occurs in 0.5–2% of open-heart procedures; the incidence has decreased with improved surgical technique and routine post-operative echocardiography.
  • Tuberculous pericarditis, though uncommon nationally, remains an important cause in immunocompromised populations and some remote communities. Australia records approximately 1,300 new TB notifications per year (AIHW, 2023).
  • Uraemic pericarditis causing tamponade is seen in patients with end-stage kidney disease, particularly those with delayed or inadequate dialysis.
  • Idiopathic and viral pericarditis accounts for a significant proportion of pericardial effusions, though most do not progress to tamponade.
⚠️
Time-critical emergency: Cardiac tamponade can deteriorate rapidly to cardiac arrest. Any patient with unexplained hypotension, elevated JVP, and muffled heart sounds should be assumed to have tamponade until proven otherwise, and emergency echocardiography should be performed immediately.
Cardiac Tamponade clinical infographic β€” pathophysiology, clinical clues, diagnosis, imaging, and management
Tap or click image to enlarge β€” Cardiac Tamponade: pathophysiology, clinical clues, diagnosis, imaging, and management.
Cardiac Tamponade infographic, full size

Clinical Recognition

Beck's Triad

The classic triad described by Claude Beck in 1935 comprises:

1
Hypotension
Decreased systolic blood pressure reflecting reduced stroke volume. Often narrow pulse pressure (<30 mmHg) due to compensatory vasoconstriction.
2
Muffled Heart Sounds
Distant or attenuated heart sounds on auscultation due to fluid cushioning between the heart and chest wall. May be difficult to detect in noisy environments.
3
Jugular Venous Distension (JVD)
Elevated central venous pressure causing visible distension of the internal jugular veins. The x-descent is preserved (rapid atrial relaxation) while the y-descent is attenuated (impaired ventricular filling).
ℹ️
Clinical caveat: Complete Beck's triad is present in only 30–40% of patients with cardiac tamponade. Hypotension may be absent early due to compensatory mechanisms, and JVD may be masked by hypovolaemia. Maintain a high index of suspicion.

Pulsus Paradoxus

Pulsus paradoxus is defined as an inspiratory decrease in systolic arterial blood pressure of >10 mmHg. It is the most sensitive clinical sign for cardiac tamponade, present in up to 80% of cases.

Measurement technique:

  1. Use a sphygmomanometer with the patient breathing normally (avoid deep breaths).
  2. Slowly deflate the cuff (2–3 mmHg per heartbeat).
  3. Note the pressure at which Korotkoff sounds are first heard (typically only during expiration).
  4. Continue deflating until Korotkoff sounds are heard throughout the respiratory cycle.
  5. The difference between these two values is the degree of pulsus paradoxus.
🚨
Limitations of pulsus paradoxus: Pulsus paradoxus is unreliable in patients with severe hypotension (SBP <90 mmHg), atrial septal defect, aortic regurgitation, severe left ventricular dysfunction, or positive-pressure ventilation. Its absence does NOT exclude tamponade.

Echocardiographic Signs

Transthoracic echocardiography (TTE) is the primary diagnostic modality for cardiac tamponade. Key findings include:

Echocardiographic Sign Description Sensitivity / Specificity
Right Atrial (RA) Collapse Inward bowing of the RA free wall in late diastole / early systole (when RA pressure exceeds intrapericardial pressure). Duration >1/3 of the cardiac cycle is highly specific for tamponade. Sensitivity 50–60%, Specificity ~95%
Right Ventricular (RV) Collapse Inward bowing of the RV free wall in early diastole. More specific than RA collapse for tamponade physiology. Indicates higher intrapericardial pressures. Sensitivity 60–90%, Specificity ~80–90%
IVC Plethora Inferior vena cava diameter >2.1 cm with <50% inspiratory collapse (in spontaneously breathing patients). Reflects elevated right atrial pressure. Sensitivity ~90%, Specificity ~50%
Respiratory Variation in Flow Velocities >25% variation in mitral inflow E velocity and >40% variation in tricuspid inflow E velocity with respiration. Detected on pulse-wave Doppler. Sensitivity ~80%, Specificity ~85%
Swinging Heart Excessive cardiac motion within a large effusion β€” pendular swinging. Seen in large, often malignant effusions. Low sensitivity; specific for large effusions
⚠️
Emergency echo should not be delayed: In any haemodynamically unstable patient with suspected pericardial effusion, point-of-care ultrasound (POCUS) should be performed at the bedside immediately. Do not wait for a formal cardiology echocardiogram β€” the treating clinician should perform a focused cardiac ultrasound without delay.

Additional Clinical Features

  • Tachycardia β€” compensatory increase in heart rate to maintain cardiac output.
  • Tachypnoea β€” respiratory distress from diaphragmatic compression and reduced cardiac output.
  • Electrical alternans on ECG β€” beat-to-beat variation in QRS amplitude caused by the heart swinging within the pericardial fluid. Highly specific but seen in only ~10% of tamponade cases. Low voltage QRS is more common.
  • Pericardial knock β€” an early diastolic sound occasionally auscultated due to sudden cessation of ventricular filling.
  • Hepatojugular reflux β€” sustained JVP elevation with right upper quadrant pressure (>3 cm increase sustained for >10 seconds).
  • Cool peripheries, oliguria, and altered mental status indicate progressed obstructive shock.

Haemodynamic Consequences

Understanding the haemodynamic derangements of cardiac tamponade is essential for rational management. The fundamental pathophysiology is restriction of cardiac filling by elevated intrapericardial pressure.

Pathophysiology of Impaired Filling

  • As pericardial fluid accumulates, intrapericardial pressure rises according to the pericardial pressure–volume relationship. The normal pericardium has limited compliance; once its reserve volume is exhausted, small additional volumes cause steep pressure increases.
  • Elevated intrapericardial pressure is transmitted to all four cardiac chambers, compressing them and restricting diastolic filling.
  • The right-sided chambers (RA and RV) are more compliant and therefore collapse first. Left-sided collapse occurs only in severe or rapidly accumulating tamponade.

Equalisation of Pressures

The haemodynamic hallmark of tamponade is the equalisation of intracardiac diastolic pressures with intrapericardial pressure. All of the following pressures converge to within 5 mmHg of each other:

Pressure Normal (mmHg) Tamponade (mmHg)
Intrapericardial pressure <0 (sub-atmospheric) Elevated (equal to diastolic pressures)
Right atrial pressure (mean) 2–6 12–20
RV end-diastolic pressure 1–5 12–20
Pulmonary capillary wedge pressure 6–12 12–20
LV end-diastolic pressure 5–12 12–20
ℹ️
Diagnostic confirmation: Right heart catheterisation demonstrating equalisation of diastolic pressures across all chambers is the gold standard haemodynamic confirmation of tamponade. This is rarely required when echocardiographic and clinical findings are concordant.

Decreased Cardiac Output

  • Impaired diastolic filling leads to reduced end-diastolic volume (preload).
  • Stroke volume falls according to the Frank-Starling mechanism.
  • Cardiac output is further compromised during inspiration β€” venous return to the right heart increases, but the ventricular septum bulges leftward (ventricular interdependence), reducing LV filling and output. This is the mechanism of pulsus paradoxus.
  • In advanced tamponade, cardiac output becomes insufficient to maintain end-organ perfusion, resulting in obstructive shock.

Compensatory Tachycardia

  • Baroreceptor-mediated sympathetic activation increases heart rate to compensate for reduced stroke volume and maintain cardiac output (CO = HR Γ— SV).
  • Systemic vascular resistance (SVR) rises via catecholamine-driven vasoconstriction, maintaining blood pressure initially but reducing peripheral perfusion.
  • This compensatory phase may mask the severity of haemodynamic compromise β€” patients can appear relatively stable until sudden decompensation.
  • Beta-blockers or calcium channel blockers may blunt the compensatory tachycardia and precipitate haemodynamic collapse in patients with undiagnosed tamponade.
🚨
Avoid negative inotropes: Beta-blockers, non-dihydropyridine calcium channel blockers (verapamil, diltiazem), and other myocardial depressants are contraindicated in cardiac tamponade. These agents eliminate the compensatory tachycardia and can precipitate cardiovascular collapse. If the patient is taking these medications, consider withholding or reversing their effects.

Progression to Obstructive Shock

Early
Compensated state β€” tachycardia, peripheral vasoconstriction, preserved blood pressure with narrow pulse pressure. Patient may appear anxious, diaphoretic.
Moderate
Hypotension (SBP <90 mmHg), pronounced JVD, pulsus paradoxus >10 mmHg, cold peripheries, oliguria. Venous oxygen saturation falling.
Late / Decompensated
Severe hypotension or unmeasurable BP, altered consciousness, bradycardia (pre-terminal), agonal breathing. Imminent PEA arrest.
Arrest
Pulseless electrical activity (PEA). Resuscitative thoracotomy and emergency surgical drainage required if pericardiocentesis is not immediately available.

Emergency Management

Cardiac tamponade is a medical emergency requiring immediate intervention. The goals of initial management are to maintain cardiac output temporise while arranging definitive pericardial drainage.

Immediate Resuscitation Measures

1
Call for Help Early
Activate the medical emergency team (MET/RRT). Simultaneously contact cardiology and cardiothoracic surgery. Ensure the resuscitation bay is prepared.
2
Volume Resuscitation
Administer IV crystalloid bolus 500–1000 mL (0.9% sodium chloride or compound Ringer's lactate) over 15–20 minutes. Volume expansion increases right-sided filling pressures, temporarily overcoming intrapericardial pressure. May require repeat boluses. Cautious in patients with suspected left ventricular dysfunction.
3
Avoid Positive-Pressure Ventilation
Positive intrathoracic pressure (NIV, CPAP, invasive ventilation) reduces venous return to the right heart and can precipitate cardiovascular collapse. Avoid intubation unless absolutely necessary for airway protection. If intubation is unavoidable, use reduced tidal volumes and minimal PEP/PEEP, with vasopressor support ready.
4
Patient Positioning
Position the patient sitting upright and leaning forward if tolerated β€” this position may relieve venous compression and improve comfort. Avoid the supine position if possible.
5
Vasopressor Support
If hypotension persists despite volume resuscitation, commence vasopressor infusion. Noradrenaline 0.05–0.5 mcg/kg/min IV is the preferred first-line agent, maintaining SVR while preserving heart rate. Adrenaline (0.01–0.1 mcg/kg/min) may be considered in severe shock. Note: vasopressors are a temporising measure only β€” they do not substitute for drainage.
6
Bedside Echocardiography
Perform point-of-care ultrasound (POCUS) to confirm pericardial effusion, assess for signs of tamponade (RA/RV collapse, IVC plethora), estimate effusion size, and guide pericardiocentesis. Do not delay for a formal study if the patient is haemodynamically unstable.
🚨
If PEA arrest occurs: Begin standard ALS protocols. Suspect tamponade as the cause in any PEA arrest with known pericardial effusion, recent cardiac surgery, or penetrating chest trauma. Emergency pericardiocentesis (blind or ultrasound-guided) or resuscitative thoracotomy (in the ED with surgical capability) should be performed without delay.

Medications to Avoid

Drug / Intervention Risk
Beta-blockers (metoprolol, atenolol, carvedilol) Eliminate compensatory tachycardia β†’ cardiovascular collapse
Non-dihydropyridine CCBs (verapamil, diltiazem) Negative chronotrope and inotrope β†’ haemodynamic deterioration
Diuretics (furosemide, hydrochlorothiazide) Reduce preload β†’ critically worsens cardiac output in tamponade
Positive-pressure ventilation (NIV, invasive with high PEEP) Reduces venous return β†’ precipitous fall in cardiac output
Vasodilators (GTN, sodium nitroprusside) Reduce afterload and preload β†’ worsened hypotension

Indications for Emergent vs Urgent Drainage

Emergent
Immediate Pericardiocentesis
Haemodynamic instability (SBP <90 mmHg, shock, altered consciousness), cardiac arrest (PEA), impending cardiac arrest despite resuscitation.
Setting: Bedside in ED / ICU / Cath lab β€” do NOT delay for transfer
Urgent
Drainage Within Hours
Stable haemodynamics with echocardiographic signs of tamponade (RA/RV collapse), moderate–large effusion, clinical tamponade signs present. Allow time for echo-guided approach and sterile preparation.
Setting: Catheterisation lab or procedural suite with echo guidance
Elective
Planned Drainage
Large effusion without tamponade physiology on echocardiography (no chamber collapse, normal IVC). Drain to prevent tamponade or for diagnostic fluid analysis (e.g., suspected malignancy, TB).
Setting: Cardiology procedural suite under elective list

Pericardiocentesis

Indications

  • Cardiac tamponade (haemodynamically compromised) β€” emergent
  • Large pericardial effusion with echocardiographic signs of impending tamponade β€” urgent
  • Diagnostic pericardiocentesis β€” suspected purulent pericarditis, tuberculosis, or malignancy
  • Therapeutic drainage for symptomatic large effusion (dyspnoea, chest discomfort)
  • Post-cardiac surgery tamponade (if catheter drainage feasible; otherwise surgical re-exploration)

Contraindications

  • Absolute: Uncontrolled bleeding diathesis (INR >2.0, platelets <50 Γ— 10⁹/L) β€” unless emergent and bleeding risk is outweighed by immediate risk of death.
  • Relative: Loculated effusion (may require surgical drainage), aortic dissection with haemopericardium, posterior/dominant effusion inaccessible from subxiphoid approach.
  • Note: In emergent tamponade, there are virtually no absolute contraindications β€” delay is more dangerous than the procedure.

Technique β€” Subxiphoid Approach

The subxiphoid (inferior) approach is the most commonly used technique for pericardiocentesis and is the recommended default approach, particularly in emergency settings.

1
Preparation
Position the patient at 30–45Β° head-up (if tolerated). Administer supplemental oxygen. Establish IV access. Connect continuous ECG monitoring. Prepare sterile field. Administer local anaesthesia (1–2% lignocaine, up to 3 mg/kg) infiltrating skin, subcutaneous tissue, and deeper tissues along the needle trajectory.
2
Landmark Identification
Identify the subxiphoid notch (junction of the xiphoid process and the left costal margin). The needle insertion point is 1–2 cm inferior and 1–2 cm to the left of the xiphoid process. Ultrasound guidance should be used to confirm the optimal puncture site and needle trajectory (towards the left shoulder at approximately 30–45Β° to the skin).
3
Needle Insertion
Attach a syringe to a 16–18 gauge pericardiocentesis needle (or Tuohy needle for catheter insertion). Advance the needle slowly, aspirating continuously, towards the left shoulder. A change in resistance (a "give") may be felt as the needle enters the pericardial space. Aspiration of fluid confirms entry. If using ECG guidance (back-up), attach the V-lead to the needle via a sterile cable β€” ST elevation indicates epicardial contact; withdraw slightly.
4
Catheter Placement
Once pericardial fluid is aspirated, pass a J-wire through the needle into the pericardial space. Remove the needle over the wire. Dilate the tract. Insert a multi-side-hole pigtail catheter (6–8 Fr) over the wire. Secure the catheter with sutures and apply a sterile dressing. Connect to a drainage bag via a three-way tap.
5
Drainage
Drain fluid slowly β€” no more than 500 mL at initial drainage to avoid acute right ventricular dilatation. Monitor haemodynamics continuously during drainage. Send fluid for analysis (see Post-Drainage Care). Clamp the catheter and re-open periodically for intermittent drainage, or allow continuous slow drainage.

Imaging Guidance

Modality Advantages Limitations
Echocardiography-guided (preferred) Real-time needle visualisation, identifies optimal puncture site, confirms pericardial entry, reduces complication rate (<1%), available at bedside Operator-dependent; limited acoustic windows in obese, ventilated, or post-surgical patients
Fluoroscopy-guided Useful in catheterisation laboratory setting, good for catheter positioning Radiation exposure; requires transfer to cath lab; does not directly visualise the needle–heart relationship
CT-guided Excellent for loculated, posterior, or complex effusions Not real-time; requires transfer; time-consuming; not suitable for emergencies
Blind (landmark-only) No imaging required; can be performed anywhere immediately Higher complication rate (~5%); reserved for cardiac arrest or extreme emergencies with no imaging available
⚠️
Always use image guidance when possible: Echocardiography-guided pericardiocentesis is the standard of care for all non-arrest situations. The Australian Commission on Safety and Quality in Health Care (ACSQHC) recommends ultrasound guidance for all invasive procedures where feasible, in line with the National Safety and Quality Health Service (NSQHS) Standards.

Complications of Pericardiocentesis

Complication Incidence (echo-guided) Management
Cardiac chamber puncture (RV most common) 0.5–1% Usually self-limiting; withdraw needle. Echocardiographic monitoring. Surgical repair if persistent bleeding.
Coronary artery laceration <0.5% Emergency surgical repair. Angiography and stenting if feasible.
Pneumothorax 0.5–1% Observation if small; intercostal catheter insertion if significant.
Arrhythmia (ventricular ectopy) 1–3% Withdraw needle; usually resolves. Anti-arrhythmic if sustained.
Recurrent effusion 10–30% (depends on aetiology) Repeat drainage; consider indwelling catheter, surgical pericardial window, or pericardiodesis.
Vagal reaction 1–2% Atropine 600 mcg IV if bradycardic. Trendelenburg positioning.

Surgical Alternatives

Consider surgical drainage (pericardial window) when:

  • Loculated effusion not amenable to percutaneous drainage
  • Recurrent tamponade despite catheter drainage
  • Haemorrhagic effusion (post-cardiac surgery, trauma, coagulopathy)
  • Purulent pericarditis requiring thorough debridement
  • Need for pericardial biopsy for diagnosis (suspected TB, malignancy)
  • Aortic dissection with tamponade (emergent surgical repair)

Surgical approaches include subxiphoid pericardial window (local or general anaesthesia), video-assisted thoracoscopic surgery (VATS) pericardial window, and median sternotomy. The subxiphoid window is the most common surgical approach, providing reliable drainage with lower morbidity than thoracotomy.

πŸ–ΌοΈ Cardiac Tamponade β€” visual summary
Cardiac Tamponade visual summary infographic

Post-Drainage Care

Fluid Analysis

All pericardial fluid specimens should be sent for comprehensive analysis to identify the underlying aetiology:

Investigation Purpose Key Findings
Gross appearance Initial assessment Serous (inflammatory/idiopathic), serosanguinous (malignancy, TB, post-MI), frankly bloody (trauma, malignancy, coagulopathy), purulent (bacterial infection), chylous (lymphatic obstruction)
Cell count & differential Inflammatory vs. malignant vs. infective Neutrophil predominance β†’ bacterial infection; lymphocyte predominance β†’ TB, viral, malignancy; elevated RBC β†’ haemorrhagic
Protein & LDH Exudate classification (Light's criteria adapted) Pericardial/serum protein ratio >0.5 or pericardial/serum LDH ratio >0.6 β†’ exudate
Glucose Infection / rheumatoid Very low (<1.1 mmol/L) β†’ bacterial or tuberculous pericarditis, rheumatoid
Gram stain & culture Bacterial infection Low sensitivity (~50%); send blood cultures simultaneously. Consider 16S rRNA PCR.
AFB stain, culture & PCR Tuberculosis AFB culture takes 2–6 weeks; GeneXpert MTB/RIF on pericardial fluid has sensitivity ~60–70% and rapid turnaround
Adenosine deaminase (ADA) TB screening ADA >40 U/L strongly suggestive of tuberculous pericarditis in endemic populations
Cytology Malignancy Sensitivity 70–90% for malignant effusion; send β‰₯50 mL for optimal yield. Consider cell block preparation.
Fluid pH Infection pH <7.0 β†’ purulent pericarditis (empyema)

Monitoring for Reaccumulation

  • Perform repeat echocardiography within 24–48 hours of drainage, then as clinically indicated (typically at 1 week, 1 month, and 3 months).
  • Monitor the volume and character of fluid draining via the indwelling catheter β€” decreasing output suggests successful drainage; sudden cessation may indicate catheter blockage.
  • The pericardial catheter is typically removed when drainage volume falls to <25–50 mL per 24 hours and repeat echocardiography shows no significant reaccumulation.
  • Patients should be monitored in a high-dependency or cardiac monitoring setting for at least 24 hours post-drainage, with continuous telemetry and frequent vital sign assessment.
  • Recurrence rates vary by aetiology: idiopathic/viral (~10–15%), malignancy (~30–50% without definitive treatment), uraemic (responds to dialysis), TB (responds to anti-tuberculous therapy).
⚠️
Malignant pericardial effusion recurrence: Patients with malignant effusion have high recurrence rates. Consider early cardiology/cardiothoracic consultation for pericardial window, pericardiodesis (sclerotherapy with bleomycin or talc), or indwelling pericardial catheter for outpatient drainage. Discuss goals of care in the context of the patient's overall oncological prognosis.

Addressing Underlying Aetiology

🦠
Tuberculous Pericarditis
Anti-tuberculous therapy Β± corticosteroids
Regimen (2HRZE/4HR) Isoniazid 300 mg PO daily + Rifampicin 600 mg PO daily (450 mg if <50 kg) + Pyrazinamide 25 mg/kg PO daily (max 2 g) + Ethambutol 15 mg/kg PO daily for 2 months, then Isoniazid + Rifampicin for 4 months
Adjunctive corticosteroids Prednisolone 60 mg PO daily for 2 weeks, taper over 6–12 weeks (RHDAustralia recommendation). Reduces mortality and need for repeat drainage.
PBS status βœ” PBS Authority Required
πŸ₯
Bacterial (Purulent) Pericarditis
Empirical IV antibiotics β€” eTG Antibiotic
Empirical regimen Vancomycin 25–30 mg/kg IV loading then 15–20 mg/kg IV BD (adjusted to trough 15–20 mg/L) + Ceftriaxone 2 g IV daily. Add rifampicin if staphylococcal prosthetic material involved.
Duration 4–6 weeks IV antibiotics minimum. Surgical drainage/debridement usually required in addition.
PBS status βœ” PBS General Benefit
πŸ§ͺ
Uraemic Pericarditis
Intensified dialysis
Management Intensify haemodialysis (daily or alternate-day) to achieve adequate clearance. Pericardial effusion typically resolves with improved dialysis. Pericardiocentesis only if tamponade develops. Avoid heparin in dialysis circuit if haemopericardium suspected.
PBS status βœ” PBS General Benefit (dialysis)
πŸ’Š
Hypothyroidism (Myxoedema Pericardial Effusion)
Levothyroxine replacement
Adult dose Levothyroxine 50–100 mcg PO daily initially, titrate by 25 mcg every 4–6 weeks based on TSH. Elderly/ischaemic heart disease: start 25 mcg daily.
Note Pericardial effusion in hypothyroidism is usually chronic and rarely causes tamponade. Effusion resolves slowly with thyroid replacement over weeks to months.
PBS status βœ” PBS General Benefit
πŸ”¬
Malignant Pericardial Effusion
Oncological therapy + drainage strategies
Systemic therapy Chemotherapy, immunotherapy, or targeted therapy as determined by tumour type and oncology team (refer to eviQ protocols).
Local therapy Pericardiodesis with bleomycin (60 units intrapericardial) or talc slurry via surgical window. Indwelling pericardial catheter for ongoing outpatient drainage.
PBS status βœ” PBS Authority Required (oncology agents)
πŸ«€
Idiopathic / Viral Pericarditis
NSAIDs + colchicine
First-line Ibuprofen 600 mg PO TDS for 1–2 weeks, taper over 2–3 weeks. Or aspirin 750–1000 mg PO TDS.
Adjunctive Colchicine 500 mcg PO BD for 3 months (to reduce recurrence). Weight-based: <70 kg β†’ 500 mcg BD.
Renal adjustment Avoid NSAIDs in eGFR <30 mL/min. Colchicine: dose reduce in severe renal impairment; avoid in dialysis.
PBS status βœ” PBS General Benefit

Discharge Planning & Follow-Up

  • Ensure the underlying aetiology has been identified and treatment initiated before discharge (or a clear management plan is in place).
  • Arrange cardiology follow-up within 1–2 weeks of discharge with repeat echocardiography.
  • Provide the patient with written warning signs of recurrence: increasing dyspnoea, chest pain, presyncope, palpitations, peripheral oedema.
  • Advise the patient to present to the emergency department immediately if symptoms recur.
  • For patients on NSAIDs/colchicine, schedule GP review at 2 and 6 weeks to assess response and monitor renal function.

Special Populations

🀰 Pregnancy
Pericardiocentesis Safe in pregnancy when indicated for tamponade. Echo-guided subxiphoid approach is preferred. Shield the abdomen if fluoroscopy is used (emergencies only).
Haemodynamic monitoring Left lateral tilt (15–30Β°) to avoid aortocaval compression. Continuous fetal monitoring if gestational age β‰₯24 weeks. Obstetric and neonatal teams should be notified.
Medication considerations Avoid colchicine in pregnancy (Category B3 β€” teratogenic in animal studies). NSAIDs are contraindicated in the third trimester (risk of premature closure of the ductus arteriosus). Paracetamol for analgesia. Discuss corticosteroid use with obstetrician.
Underlying aetiology Consider peripartum cardiomyopathy, pre-eclampsia-related effusion, and viral pericarditis. TB and malignancy should still be investigated if clinically suspected.
πŸ‘Ά Paediatrics
Aetiology Common causes include post-cardiac surgery (most frequent), malignancy (leukaemia, lymphoma), bacterial infection (Staphylococcus aureus, Haemophilus influenzae in unvaccinated), viral pericarditis, and rheumatic fever.
Clinical recognition Beck's triad may be difficult to assess in infants. Tachycardia and hepatomegaly are often the earliest signs. Low threshold for echocardiography in any post-operative cardiac patient with unexplained haemodynamic instability.
Pericardiocentesis needle Use smaller gauge needle (18–20 G) appropriate to patient size. Echo guidance is essential. Paediatric cardiology consultation should be obtained whenever possible.
Volume resuscitation 20 mL/kg 0.9% NaCl bolus, repeat as needed. Maximum 60 mL/kg in the first hour unless fluid overload is evident.
πŸ‘΄ Elderly
Atypical presentation Elderly patients may present with confusion, falls, or generalised weakness rather than classic tamponade features. Maintain a high index of suspicion in frail patients with unexplained hypotension.
Comorbidities Higher prevalence of malignancy, uraemia (CKD), hypothyroidism, and post-procedural effusion (post-PCI, post-surgery). Careful assessment of bleeding risk prior to pericardiocentesis β€” review anticoagulant and antiplatelet medications.
Volume resuscitation caution Cautious fluid boluses (250 mL increments) in patients with known heart failure or LV dysfunction β€” risk of fluid overload after tamponade is relieved.
Anticoagulant management Hold warfarin (aim INR <1.5 for procedure). Hold DOACs for 24–48 hours if possible (emergencies excepted). Hold clopidogrel/ticagrelor if safe to do so. Balance thrombotic vs. bleeding risk with haematology/cardiology input.
🫘 Renal Impairment
Uraemic pericarditis Most common in patients with eGFR <15 mL/min not on dialysis or with inadequate dialysis. Distinguish from other causes β€” not all pericardial effusions in CKD are uraemic.
Fluid balance Volume resuscitation should be cautious in patients with oliguria/anuria β€” risk of pulmonary oedema after tamponade relief and fluid administration. Plan for early dialysis post-drainage if volume overloaded.
Drug adjustments NSAIDs contraindicated in eGFR <30. Colchicine reduce dose in eGFR <30 and avoid in dialysis. Antibiotic doses adjusted per renal function (vancomycin, gentamicin AUC-guided dosing).
🫁 Hepatic Impairment
Coagulopathy Patients with liver disease may have significant coagulopathy (elevated INR, thrombocytopaenia). Assess coagulation profile prior to pericardiocentesis. Correct with FFP, cryoprecipitate, or platelets if INR >2.0 or platelets <50 Γ— 10⁹/L.
Hepatocellular carcinoma Consider as a cause of malignant pericardial effusion in patients with chronic liver disease/hepatitis B/C, particularly in ATSI communities with higher HBV prevalence.
Drug metabolism Reduce doses of hepatically cleared drugs. Colchicine dose reduction in hepatic impairment. Avoid or reduce rifampicin dose monitoring in severe liver disease β€” discuss with infectious disease service.
πŸ›‘οΈ Immunocompromised
Expanded differential Consider TB, fungal pericarditis (Aspergillus, Cryptococcus in HIV/organ transplant), CMV, and opportunistic bacterial infections in addition to malignancy.
HIV-positive patients Pericardial effusion is common (up to 20% on echocardiography). Usually due to TB in Australian settings. Send fluid for TB PCR (GeneXpert MTB/RIF), ADA, and cytology. Initiate ART alongside anti-TB therapy β€” immune reconstitution may worsen effusion transiently.
Post-transplant patients Post-cardiac transplant pericardial effusion occurs in 10–20%. Consider acute cellular rejection (endomyocardial biopsy indicated), infection, and post-surgical causes. Manage in conjunction with the transplant team.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health
Tuberculous pericarditis
TB incidence is 6–8 times higher in Aboriginal and Torres Strait Islander peoples compared to non-Indigenous Australians (AIHW, 2023). TB pericarditis should be actively considered in any ATSI patient presenting with pericardial effusion, particularly in remote and northern communities. Ensure pericardial fluid is sent for GeneXpert MTB/RIF, AFB culture, and ADA level. Initiate treatment under guidance from the TB unit and RHDAustralia protocols.
Rheumatic heart disease (RHD)
RHD remains disproportionately prevalent in Aboriginal and Torres Strait Islander communities, particularly in the Northern Territory, Queensland, and Western Australia. Pericarditis is a recognised manifestation of acute rheumatic fever. Pericardial effusion in a young ATSI patient should prompt investigation for ARF/RHD (ASOT, anti-DNase B, echocardiography) and notification to the RHD register as per jurisdictional requirements.
Remote access to echocardiography
Point-of-care ultrasound (POCUS) is increasingly available in remote health centres through the Australian Government's Rural Health Outreach Fund and RFDS. However, access to formal echocardiography and cardiology expertise is limited. The Royal Flying Doctor Service (RFDS) and specialist outreach programs (e.g., Top End Health Service cardiology outreach) provide some access, but delays in diagnosis are common. Tele-echocardiography with remote specialist interpretation is an evolving solution.
Transfer considerations
Patients in remote communities with suspected tamponade require emergent aeromedical retrieval. RFDS and state retrieval services (e.g., NT Retrieval Service, Queensland Retrieval Service) can provide remote consultation and facilitate urgent transfer. In the interim, commence IV fluid resuscitation and arrange bedside pericardiocentesis using POCUS guidance if the patient is deteriorating and transfer is delayed. Ensure Cultural Safety during transfer β€” involve family, maintain communication, and consider the patient's preference for care location where safe to do so.
Chronic kidney disease
End-stage kidney disease (ESKD) is 4–6 times more prevalent in Aboriginal and Torres Strait Islander peoples (ANZDATA, 2023). Uraemic pericarditis is a significant cause of pericardial effusion and tamponade in this population. Access to adequate dialysis is a challenge in many remote communities β€” patients may require relocation to regional centres. Ensure regular monitoring of renal function and dialysis adequacy in ATSI patients with CKD to prevent uraemic pericarditis.
Cultural Safety & communication
Use professional Aboriginal and Torres Strait Islander health practitioners and interpreter services where available (e.g., Aboriginal Interpreter Service in the NT). Explain the procedure, risks, and benefits in plain language and in the patient's preferred language. Respect family and community involvement in decision-making. Be aware of Sorry Business and cultural obligations that may affect the patient's availability for follow-up. Document advance care preferences where relevant.
πŸ“Š Cardiac Tamponade β€” slide deck

Open slides PDF in new tab

πŸ“š References

  1. 1. Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases. Eur Heart J. 2015;36(42):2921–2964.
  2. 2. Spodick DH. Acute cardiac tamponade. N Engl J Med. 2003;349(7):684–690.
  3. 3. Imazio M, Adler Y. Management of pericardial effusion. Eur Heart J. 2013;34(16):1186–1197.
  4. 4. Klein AL, Abbara S, Agler DA, et al. American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease. J Am Soc Echocardiogr. 2013;26(9):965–1012.e15.
  5. 5. Tsang TSM, Enriquez-Sarano M, Freeman WK, et al. Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses: clinical profile, practice patterns, and outcomes spanning 21 years. Mayo Clin Proc. 2002;77(5):429–436.
  6. 6. Rabindranath KS, Shrestha B, Papineni S, et al. Echocardiography-guided pericardiocentesis versus landmark-guided pericardiocentesis: a systematic review and meta-analysis. Int J Cardiol. 2017;228:729–735.
  7. 7. Australian Institute of Health and Welfare (AIHW). Tuberculosis notifications in Australia 2023. AIHW; 2024.
  8. 8. RHDAustralia (Rheumatic Heart Disease Australia). The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  9. 9. Maisch B, SeferoviΔ‡ PM, RistiΔ‡ AD, et al. Guidelines on the diagnosis and management of pericardial diseases. Eur Heart J. 2004;25(7):587–610.
  10. 10. Imazio M, Brucato A, Cemin R, et al. A randomized trial of colchicine for acute pericarditis (COPE trial). N Engl J Med. 2013;369(16):1522–1528.
  11. 11. ANZDATA Registry. 46th Annual Report 2023. Adelaide: Australia and New Zealand Dialysis and Transplant Registry; 2023.
  12. 12. Hancock EW. Cardiac tamponade. Med Clin North Am. 1979;63(1):223–237.
  13. 13. American Heart Association. Advanced Cardiovascular Life Support (ACLS) Provider Manual. Dallas: AHA; 2020.
  14. 14. Australian Commission on Safety and Quality in Health Care (ACSQHC). National Safety and Quality Health Service Standards. 2nd ed. Sydney: ACSQHC; 2021.
  15. 15. Willner DA, Goyal A, Grigorova Y, et al. Pericardiocentesis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024.